Novo Nordisk shares plunge after heart-disease drug trial fails
Novo Nordisk said a late-stage clinical trial of its heart-disease drug ziltivekimab failed to show that the treatment was more effective than a placebo at reducing major adverse cardiovascular events. The company's shares subsequently fell as much as 10%.
Novo Nordisk said a late-stage clinical trial of its heart-disease drug ziltivekimab failed to show that the treatment was more effective than a placebo at reducing major adverse cardiovascular events. The company's shares subsequently fell as much as 10%.